Inventiva (Euronext Paris and NASDAQ: IVA) has announced the appointment of biopharmaceutical leader Chris Benecchi as chief operating officer (COO).
Mr. Benecchi brings 30 years of biopharmaceutical leadership across commercial, operational and enterprise roles, with a track record of building organizations, preparing innovative investigational medicines for launch and leading cross-functional execution in competitive and access-challenged markets. Most recently, he served as CEO of closely held Motric Bio.
In a statement, Andrew Obenshain, CEO of Inventiva, commented, “This is a defining moment for Inventiva. We believe lanifibranor, if approved, has the potential to offer a differentiated approach for the treatment of MASH. As we approach our Phase 3 readout, we are preparing the Company for the next stage of its evolution. Chris brings a valuable combination of commercial, operational and launch experience, with a proven track record of helping organizations bring promising medicines to patients. His experience is particularly relevant to the opportunity in the dynamic MASH market. I’m thrilled to have Chris lead this next phase of our journey.”
Mr. Benecchi remarked, “Leveraging the strong scientific foundation and the opportunity to address unmet patient needs, I am joining Inventiva with a clear mandate to build the organization and capabilities needed to prepare for the potential launch of lanifibranor and to position the Company for sustainable long-term success. We believe lanifibranor is poised to meaningfully impact the current treatment paradigm in MASH. I look forward to leading this work with the team to fulfill that promise in the interest of patients.”
